314 studies found for:    "Multiple Sclerosis, Relapsing-Remitting"
Show Display Options
Rank Status Study
21 Completed A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients "TIMER" Study
Condition: Relapsing Remitting Multiple Sclerosis (RRMS)
Intervention: Drug: Natalizumab (Tysabri®)
22 Completed Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Rebif (Interferon beta-1a)
23 Completed Atorvastatin in Relapsing-Remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: interferon beta treatment to add-on atorvastatin treatment;   Drug: untreated to atorvastatin treatment
24 Recruiting Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Device: Rebif® Rebidose®;   Device: Rebiject II®
25 Completed BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: BHT-3009 0.5 mg;   Drug: BHT-3009 1.5 mg;   Drug: Placebo
26 Completed Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Natalizumab;   Drug: Placebo
27 Active, not recruiting A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: abatacept;   Drug: Placebo
28 Completed A Study of Patients With Relapsing Remitting Multiple Sclerosis
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: LY2127399;   Drug: Placebo
29 Completed A Study for Patients With Relapsing Remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: dirucotide;   Drug: placebo
30 Active, not recruiting Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Biological: Helminth ova
31 Completed ACT-128800 in Relapsing-remitting Multiple Sclerosis
Condition: Relapsing-remitting Multiple Sclerosis
Interventions: Drug: ACT-128800;   Drug: Placebo
32 Completed Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)
Condition: Relapsing-remitting Multiple Sclerosis
Interventions: Drug: epigallocatechin-gallate (Sunphenon);   Drug: placebo
33 Completed Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron
Conditions: Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Interferon-1beta (Betaseron, BAY86-5046)
34 Completed
Has Results
Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: BG00012;   Drug: Placebo
35 Active, not recruiting Effects of a 12-week Respiratory Muscles Training Program in Persons With Relapsing- Remitting Multiple Sclerosis
Condition: Relapsing-remitting Multiple Sclerosis
Interventions: Other: a 12-week Respiratory Muscles Training Program (RMTP);   Other: Active Comparator
36 Suspended High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Drug: Cyclophosphamide/Glatiramer acetate
37 Completed
Has Results
Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: Interferon beta 1-a;   Drug: glatiramer acetate;   Other: placebo
38 Not yet recruiting Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
Condition: Relapsing-remitting Multiple Sclerosis
Interventions: Drug: Vatelizumab SAR339658;   Drug: Placebo
39 Active, not recruiting Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study
Condition: Relapsing-remitting Multiple Sclerosis
Intervention: Drug: Ponesimod
40 Terminated Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Drug: Mitoxantrone

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years